Peptide LibraryResearch statistics
Serelaxin research: publications and trials
At a glance
Publications, all years
175
Since 2012
Publications in 2026 so far
5
Through November 1, 2026
Human clinical research
21.5%
37 of 172 classified
Registered clinical trials
17
ClinicalTrials.gov
Randomized controlled trials
30
Publications reporting an RCT in people
Systematic reviews and meta-analyses
3
Preclinical studies
41.3%
58 animal · 13 in vitro · 0 computational
Records that only mention it
68
Not counted above
Status in the library: In clinical trials. 3 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Serelaxin publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2012 | 2 | 0 | 0 | 1 | 3 |
| 2013 | 4 | 1 | 2 | 5 | 12 |
| 2014 | 3 | 6 | 9 | 3 | 21 |
| 2015 | 5 | 1 | 7 | 3 | 16 |
| 2016 | 4 | 12 | 7 | 2 | 25 |
| 2017 | 5 | 14 | 2 | 2 | 23 |
| 2018 | 3 | 4 | 3 | 0 | 10 |
| 2019 | 3 | 6 | 3 | 3 | 15 |
| 2020 | 2 | 7 | 3 | 0 | 12 |
| 2021 | 1 | 5 | 3 | 0 | 9 |
| 2022 | 1 | 7 | 5 | 0 | 13 |
| 2023 | 1 | 2 | 1 | 0 | 4 |
| 2024 | 3 | 2 | 0 | 0 | 5 |
| 2025 | 0 | 1 | 1 | 0 | 2 |
| 2026 (to date) | 0 | 3 | 0 | 2 | 5 |
Study types
| Animal study | 58 |
|---|---|
| Review | 43 |
| Randomized controlled trial | 30 |
| Editorial, letter or other | 14 |
| In vitro study | 13 |
| Correction or retraction notice | 4 |
| Other clinical trial | 3 |
| Observational human study | 3 |
| Not yet classified | 3 |
| Meta-analysis | 2 |
| Case report | 1 |
| Systematic review | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Cardiovascular | 138 |
|---|---|
| Immune system | 20 |
| Reproductive and sexual health | 18 |
| Tissue repair | 14 |
| Gastrointestinal | 7 |
| Neurological and mental health | 5 |
| Dermatology | 3 |
| Metabolic health | 3 |
| Musculoskeletal | 3 |
| Endocrinology | 2 |
| Longevity and aging | 2 |
| Cognitive health | 1 |
Registered clinical trials
1 of 11 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 11 · Terminated: 6
Phase 1: 2 · Phase 2: 12 · Phase 3: 3
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
European journal of heart failure · December 30, 2019 · Meta-analysis · cited 41 times · open access
PMID 31886953 · DOI 10.1002/ejhf.1692 · Reviews and meta-analyses
- Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis.
Medicine · June 1, 2018 · Meta-analysis · cited 3 times · open access
PMID 29923986 · DOI 10.1097/md.0000000000011010 · Reviews and meta-analyses
- Novel markers and therapies for patients with acute heart failure and renal dysfunction.
The American journal of medicine · November 13, 2014 · Systematic review · cited 14 times · open access
PMID 25446297 · DOI 10.1016/j.amjmed.2014.10.035 · Reviews and meta-analyses
- End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2).
European journal of heart failure · December 12, 2024 · Randomized controlled trial · cited 4 times · open access
PMID 39663924 · DOI 10.1002/ejhf.3551 · Human clinical research
- Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · December 1, 2024 · Randomized controlled trial · cited 11 times · open access
PMID 38782726 · DOI 10.1093/ndt/gfae112 · Human clinical research
- Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial.
European journal of heart failure · September 6, 2024 · Randomized controlled trial · cited 1 times · open access
PMID 39240040 · DOI 10.1002/ejhf.3451 · Human clinical research
- Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
Cardiovascular research · January 1, 2021 · Randomized controlled trial · cited 8 times · open access
PMID 32065620 · DOI 10.1093/cvr/cvz345 · Human clinical research
- Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2.
JACC. Heart failure · November 11, 2020 · Randomized controlled trial · cited 23 times · open access
PMID 33189635 · DOI 10.1016/j.jchf.2020.09.010 · Human clinical research
- A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP).
Trials · March 12, 2020 · Randomized controlled trial · cited 20 times · open access
PMID 32164767 · DOI 10.1186/s13063-020-4203-9 · Human clinical research
- Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial.
ESC heart failure · September 30, 2019 · Randomized controlled trial · cited 35 times · open access
PMID 31568696 · DOI 10.1002/ehf2.12477 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Lancet (London, England) · November 7, 2012 · Randomized controlled trial · cited 918 times
PMID 23141816 · DOI 10.1016/s0140-6736(12)61855-8 · Human clinical research
- Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Journal of the American College of Cardiology · January 1, 2013 · Randomized controlled trial · cited 427 times · open access
PMID 23273292 · DOI 10.1016/j.jacc.2012.11.005 · Human clinical research
- Effects of Serelaxin in Patients with Acute Heart Failure.
The New England journal of medicine · August 1, 2019 · Randomized controlled trial · cited 278 times · open access
PMID 31433919 · DOI 10.1056/nejmoa1801291 · Human clinical research
- Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF.
European journal of heart failure · October 7, 2014 · Randomized controlled trial · cited 153 times · open access
PMID 25287144 · DOI 10.1002/ejhf.170 · Human clinical research
- Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
European journal of heart failure · April 28, 2017 · Randomized controlled trial · cited 123 times · open access
PMID 28452195 · DOI 10.1002/ejhf.830 · Human clinical research
Latest publications
- Relaxin-2: Shaping the Proteomic Landscape of Skeletal Muscle Physiology, Glucose Trafficking, and Mitochondrial Function in Rat.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · September 1, 2026 · Animal study · cited 0 times · open access
PMID 42742485 · DOI 10.1096/fj.202602643r · Animal studies
- Correction to "Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1 K/DOCA/salt-induced hypertension".
British journal of pharmacology · July 15, 2026 · Correction or retraction notice · cited 0 times
PMID 42458822 · DOI 10.1111/bph.70628 · Notices
- EXPRESSION OF CONCERN: Serelaxin-Mediated Signal Transduction in Human Vascular Cells: Bell-Shaped Concentration-Response Curves Reflect Differential Coupling to G Proteins.
British journal of pharmacology · June 10, 2026 · Correction or retraction notice · cited 0 times
PMID 42272230 · DOI 10.1111/bph.70559 · Notices
- Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease.
Life sciences · May 22, 2026 · Animal study · cited 0 times · open access
PMID 42176886 · DOI 10.1016/j.lfs.2026.124472 · Animal studies
- Serelaxin alleviates ischemia reperfusion-induced kidney injury by modulating inflammatory response and inhibiting of notch-2/hes-1 signaling pathway.
Pakistan journal of pharmaceutical sciences · April 1, 2026 · Animal study · cited 0 times · open access
PMID 41761815 · DOI 10.36721/pjps.2026.39.4.reg.13820.1 · Animal studies
- Long-acting relaxin analogues: a novel tool in cardiology.
Frontiers in pharmacology · August 4, 2025 · Review · cited 1 times · open access
PMID 40832606 · DOI 10.3389/fphar.2025.1626469 · Reviews and meta-analyses
- Relaxin-2 Ameliorates Spinal Cord Injury by Inhibiting Microglia Activation.
The Kaohsiung journal of medical sciences · May 20, 2025 · Animal study · cited 1 times · open access
PMID 40392018 · DOI 10.1002/kjm2.70041 · Animal studies
- End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2).
European journal of heart failure · December 12, 2024 · Randomized controlled trial · cited 4 times · open access
PMID 39663924 · DOI 10.1002/ejhf.3551 · Human clinical research
- Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · December 1, 2024 · Randomized controlled trial · cited 11 times · open access
PMID 38782726 · DOI 10.1093/ndt/gfae112 · Human clinical research
- Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial.
European journal of heart failure · September 6, 2024 · Randomized controlled trial · cited 1 times · open access
PMID 39240040 · DOI 10.1002/ejhf.3451 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Reasanz; RLX030; Serelaxin
((TITLE_ABS:"Reasanz" OR CHEM:"Reasanz") OR (TITLE_ABS:"RLX030" OR CHEM:"RLX030" OR TITLE_ABS:"RLX 030" OR CHEM:"RLX 030") OR (TITLE_ABS:"Serelaxin" OR CHEM:"Serelaxin")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Serelaxin research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/serelaxin